title: Certolizumab pegol.
abstract: Certolizumab pegol (Cimzia(®)) is currently the only PEGylated anti-TNFα biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.
authors.affiliation: Disease Area Immunology, Global Projects and Development, UCB, Inc., Smyrna, GA USA. Niti.Goel@ucb.com
authors.forename: Niti
authors.initials: N
authors.lastname: Goel
authors.forename: Sue
authors.initials: S
authors.lastname: Stephens
mesh_terms: D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D002170:Canada; D000068582:Certolizumab Pegol; D002986:Clinical Trials as Topic; D003424:Crohn Disease / Q000188:drug therapy* / Q000276:immunology; D017277:Drug Approval; D005062:European Union; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000494:pharmacology / Q000627:therapeutic use*; D007167:Immunotherapy / Q000191:economics / Q000639:trends; D040541:Marketing; D011092:Polyethylene Glycols / Q000494:pharmacology / Q000627:therapeutic use*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology; D014481:United States
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D014409:Tumor Necrosis Factor-alpha; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol